EUTOS Score for Chronic Myelogenous Leukemia (CML)

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۱۰۰ • واحد: percentage

حداقل ۰ — حداکثر ۳۰ • واحد: cm

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
eutos score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–87
  • High Risk88–1000
Direct Clinical Answer

The EUTOS Score for Chronic Myelogenous Leukemia (CML) calculates predicting outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Key inputs include basophil percentage. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Predicts probability of complete cytogenetic response at 18 months and progression-free survival.

Clinical Indication

The EUTOS Score for Chronic Myelogenous Leukemia (CML) is indicated for bedside clinical practice to support Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Predicts probability of complete cytogenetic response at 18 months and progression-free survival.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Spleen size estimation is subjective but included in validation studies.

Formula & Variables:

EUTOS Score = (7 × basophil percentage) + (4 × spleen size in cm)

Input Parameters

NameTypeRequiredDescription
basophil_percentagefloatYesBasophils as percentage of peripheral blood leukocytes(percentage)
spleen_size_cmfloatYesSpleen size palpable below left costal margin(cm)

Score Interpretation & Guidance

RangeStageDescription
0–87Low RiskLow risk for CML progression
88–1000High RiskHigh risk for CML progression

Evidence-Based References (EBM)

  • Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul 21;118(3):686-92. doi: 10.1182/blood-2010-12-319038.DOI: 10.1182/blood-2010-12-319038
  • Hoffman R, Nagler A, Keating A, Kamel-Reid S, Lipton JH. The EUTOS score predicts outcome in CML patients treated with nilotinib front-line. Blood. 2012 Dec 6;120(23):4684; author reply 4684-5. doi: 10.1182/blood-2012-08-449249.DOI: 10.1182/blood-2012-08-449249
  • Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 update. Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569.DOI: 10.1182/blood-2013-05-501569

Related calculators